Methods and compositions for deterring abuse of opioid containing dosage forms
First Claim
Patent Images
1. A therapeutic pharmaceutical composition comprisinga mixture including(a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, β
- -hydroxy-3-methylfentanyl, levo-α
-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, prepoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt thereof;
(b) gel forming polyethylene oxide at about 3 to 40% by weight;
(c) at least one disintegrant at about 2 to 25% by weight, selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and
(d) a nasal tissue irritant, wherein the composition functions such that less than about 50% of the total amount of opioid analgesic in the composition is recovered when about 490 mg. of the composition is contacted with 15 ml of water.
14 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
347 Citations
54 Claims
-
1. A therapeutic pharmaceutical composition comprising
a mixture including (a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, β - -hydroxy-3-methylfentanyl, levo-α
-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, prepoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt thereof;(b) gel forming polyethylene oxide at about 3 to 40% by weight; (c) at least one disintegrant at about 2 to 25% by weight, selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and (d) a nasal tissue irritant, wherein the composition functions such that less than about 50% of the total amount of opioid analgesic in the composition is recovered when about 490 mg. of the composition is contacted with 15 ml of water. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
- -hydroxy-3-methylfentanyl, levo-α
-
19. A therapeutic pharmaceutical composition comprising
a mixture including (a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, β - -hydroxy-3-methylfentanyl, levo-α
-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt, thereof;(b) gel forming polyethylene oxide at about 3 to 40% by weight; (c) a surfactant at about 1 to 10% by weight; (d) at least one disintegrant at about 2 to 25% by weight, wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and (e) wherein the composition functions such that less than about 50% of the total amount of opioid analgesic in the composition is recovered when about 490 mg. of the composition is contacted with 15 ml of water. - View Dependent Claims (20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
- -hydroxy-3-methylfentanyl, levo-α
-
37. A therapeutic pharmaceutical composition comprising:
a mixture including (a) at least one opioid analgesic selected from the group consisting of alfentanil, buprenorphine, butorphanol, carfentanil, codeine, dezocine, diacetylmorphine, dihydrocodeine, dihydromorphine, diprenorphine, etorphine, fentanyl, hydrocodone, hydromorphone, β
-hydroxy-3-methylfentanyl, levo-α
-acetylmethadol, levorphanol, lofentanil, meperidine, methadone, morphine, nalbuphine, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tilidine, tramadol and a pharmaceutically acceptable salt thereof;(b) gel forming polyethylene oxide at about 3 to about 40 percent by weight; (c) at least one disintegrant at about 2 to 25 percent by weight wherein the disintegrant is selected from the group consisting of crospovidone, sodium starch glycolate, and croscarmellose sodium; and (d) sodium lauryl sulfate at about 1 to 10 percent by weight. - View Dependent Claims (38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)
Specification